Closing the Gap: Underused Consolidation Immunotherapy in Limited-Stage SCLC

In "Closing the Gap: Underused Consolidation Immunotherapy in Limited-Stage SCLC," our experts confront a stubborn disconnect between what a landmark trial proved and what patients actually receive.

Building on the ADRIATIC data, this episode confronts an uncomfortable real-world gap: despite a clear survival benefit and FDA approval, a meaningful proportion of patients who complete chemoradiotherapy for limited-stage small cell lung cancer never go on to receive consolidation durvalumab. The panel works through why. Small cell lung cancer patients frequently carry multiple comorbidities, and concurrent chemoradiation itself is a demanding regimen, so clinicians may reasonably worry about whether a patient can tolerate additional systemic therapy immediately afterward. That worry, the panel suggests, can translate into a reflexive push to complete every planned cycle of chemotherapy, even when a lower threshold for stopping early, such as three cycles instead of four, might better preserve a patient's ability to move on to consolidation.

Patient counseling emerges as a second lever. Because patients have typically only experienced conventional chemotherapy by this point, framing durvalumab explicitly as a different kind of treatment, with a substantially different toxicity and quality-of-life profile, is described as an important step in keeping patients engaged rather than treatment-averse.

The panel also shares practical workflow strategies for closing this gap. Setting expectations at the very first visit, walking patients through the full intended paradigm of chemoradiation followed by two years of consolidation, is one approach. Flexibility on timing also matters: rather than abandoning consolidation because of delays beyond the ideal 42-day window, the panel favors extending that window over skipping treatment altogether. Finally, the group flags a tendency to discontinue durvalumab too readily for lower-grade pneumonitis, arguing that with appropriate steroid management, treatment can often continue safely well beyond grade 2 toxicity, and that closing this knowledge and practice gap is itself an educational priority.

In "Patient and Practice-Level Barriers in Limited-Stage SCLC Care," the panel shifts from clinical hesitation to the logistical barriers patients themselves are navigating.